Article History
Accepted: 8 March 2024
First Online: 10 April 2024
Competing interests
: P.A.N. declares consulting relationships with Alkermes, Apollo, BMS, Exo Therapeutics, Fresh Tracks Therapeutics, Merck, Novartis, Pfizer, Qiagen and Sobi; equity in Edelweiss Immune Inc.; investigator-initiated research grants from BMS and Pfizer; and authorship and editorial income from UpToDate, the American Academy of Paediatrics and <i>Arthritis & Rheumatology</i>. M.H.C. and R.C.F. declare no competing interests.